DNA Test Firm 23andMe Can Now Tell You Your Alzheimer’s Risk Without a Prescription

The $1.1 billion Alphabet-backed Silicon Valley unicorn 23andMe just pulled off a milestone feat: On Thursday, the Food and Drug Administration (FDA) said the company could sell its genetic tests and accompanying health risk reports for ten different diseases directly to consumers.

Full Article Here